Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
  • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
  • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
  • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
  • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/45—Derivatives containing from 2 to 10 oxyalkylene groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
  • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• composition in particular cosmetic, comprising a ((dialkylamino) alkoxy) ethanoI ester
• the present invention relates to a cosmetic treatment process for wrinkled skin, comprising the topical application to said skin of a composition comprising, in a physiologically acceptable medium, at least one ((dialkylamino) alkoxy) ethanol ester of particular formula . It also relates to a new family of such compounds, as well as the cosmetic compositions containing them.
• wrinkles and fine lines have been treated with cosmetic products containing active agents which act on the skin, for example by moisturizing or improving its cell renewal or by promoting synthesis, or preventing degradation, elastic fibers that make up the skin tissue.
• active agents which act on the skin
• these treatments make it possible to act on fine lines and wrinkles due to chronological or intrinsic aging, as well as on those due to photoaging, they have no effect on expression lines, which require intervention on the muscle contractile component of wrinkles present in the skin.
• botulinum toxin which is notably injected into the glabella lines which are the inter-eyebrow lines (see JD Carruters et al., J. Dermatol Onq. Oncol., 1992,
• the Applicant has also proposed various compounds capable of offering a muscle relaxant effect when applied topically to the skin, thus making it possible to act by another route on expression wrinkles.
• these compounds mention may especially be made of the antagonists of the receptors associated with calcium channels (FR-2 793 681), and in particular manganese and its salts (FR-2 809 005) and Palverine (FR-2 798 590); and agonists of receptors associated with chlorine channels, including glycine (EP-0 704 210) and certain extracts of Iris pallida (FR-2 746 641).
• glycine EP-0 704 210
• certain extracts of Iris pallida FR-2 746 641
• the subject of the present invention is therefore a method of cosmetic treatment of wrinkled skin, in particular the skin of the face and / or forehead, comprising the topical application to said skin of a composition comprising, in a physiologically acceptable medium, at least one compound chosen from ((dialkylamino) alkoxy) ethanol esters of formula (I):
• R 1 and R 2 independently denote: a linear or branched C 1 -C 10 alkyl or alkenyl group, optionally substituted by a saturated or unsaturated carbocycle comprising from 5 to 7 carbon atoms; or a saturated or unsaturated carbocycle having from 5 to 7 carbon atoms; or Ri and R 2 form, with the nitrogen atom to which they are linked, a saturated or unsaturated heterocycle comprising from 5 to 6 atoms optionally substituted by an aryl group or by a C ⁇ -C 18 alkyl group optionally substituted by a aryl group;
• R ' and R independently denote a hydrogen atom or a linear or branched CC 6 alkyl or alkenyl group;
• n 1 to 10
• the alkyl groups can in particular be chosen, depending on the case, from the groups: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl , nonyle,ranceyle, undécyle, dodécyle, myristyle, palmityl et stéaryl.
• alkenyl is understood to mean radicals which may comprise one or more double bonds, conjugated or not. They can in particular be chosen, as the case may be, from the groups: vinyl, allyl, butenyl or pentenyl.
• the carbocycles can in particular be chosen from cyclopentyl, cyclohexyl and cycloheptyl radicals, the cyclopentyl and cyclohexyl radicals being preferred.
• the nitrogen heterocycles can in particular be chosen from piperidine, pyrrolidine, piperazine, pyrimidine and morpholine. They can therefore include, in addition to the nitrogen atom, another nitrogen atom and / or an oxygen atom.
• aryl group it is preferred to use the phenyl radical.
• salts of the ester of formula (I) mention may be made of the salts obtained by adding the ester of formula (I) with an inorganic acid, chosen in particular from hydrochloric, sulfuric and phosphoric acids, or with an acid organic, chosen in particular from succinic, fumaric, lactic, glycolic, citric, tartaric, acetic and propionic acids. Mention may also be made of the salts obtained by adding the compound of formula (I) with an inorganic base, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, and carbonates or hydrogen carbonates of sodium, potassium or calcium; or with an organic base such as triethylamine or triethanolamine.
• an inorganic acid chosen in particular from hydrochloric, sulfuric and phosphoric acids
• an acid organic chosen in particular from succinic, fumaric, lactic, glycolic, citric, tartaric, acetic and propionic acids. Mention may also be made of the salts obtained by adding the compound of formula (I) with an
• composition used according to the invention may comprise several compounds as defined above, in particular a statistical mixture of several compounds having different values of n and / or varying lengths of alkyl chain for R. This is in particular the case when the ester of formula (I) is synthesized from raw materials of plant origin.
• esters of formula (I) can in particular be prepared according to one of the conventional methods well known to those skilled in the art from amino (poly) ethoxy ethanol and acid or acid chloride correspondents.
• ester it is possible, for example, to dissolve Pamino (poly) ethoxy ethanol in a non-protic organic solvent such as dichloromethane, DMF, dioxane or THF for example, add to this solution 1 to 10 equivalents (preferably 2 eq.) of organic base such as pyridine, triethylamine, ethyldiisopropylamine or of mineral base such as sodium bicarbonate, then slowly add 1 to 10 equivalents of acid chloride (preferably 1, 2 eq). The medium is kept stirring for 1 hour to 48 hours at a temperature of 10 ° C.
• a non-protic organic solvent such as dichloromethane, DMF, dioxane or THF
• organic base such as pyridine, triethylamine, ethyldiisopropylamine or of mineral base such as sodium bicarbonate
• acid chloride preferably 1, 2 eq
• the reaction time and the temperature being a function of the medium and of the reactivity of the acid chloride used.
• the product obtained can be purified by chromatography on a column of silica gel, precipitation or recrystallization.
• ester according to route B it is possible, for example, to activate the acid function in situ with reagents widely known to those skilled in the art as described for example p.393-396 in "Advanced Organic Chemistry, Reactions , Mechanisms, and Structure ", 4rd Edition, by Jerry March, Edition Wiley-lnterscience 1992.
• the amino (poly) ethoxy ethanol can be directly heated in the presence of the carboxylic acid with or without solvent.
• the water formed is distilled directly in the case of reaction without solvent, or distilled in the form of an azeotropic mixture with the solvent such as toluene, or even trapped by a desiccant introduced into the reaction medium such as a molecular sieve or any other agent. desiccant.
• the amino (poly) ethoxy ethanol can be prepared by reaction of the corresponding secondary amine on commercial 2- (2-chloroethyl-) ethylene glycol, in methanol or acetonitrile at reflux overnight. The product thus obtained can then be treated and purified on a silica column.
• the amino (poly) ethoxy ethanol can be synthesized in particular according to the protocol described in application EP-0 300 323, starting from the corresponding polyol ether and dialkylamine.
• the compound according to the invention is such that at least one of the following conditions, and preferably all of these conditions, are satisfied: • Ri, R 2 are independently chosen from a methyl radical or ethyl; • R 3 is an unsubstituted linear C 2 -C ⁇ 9 alkyl or alkenyl radical; • n ranges from 1 to 9, preferably n is equal to 1, 2, 5 or 8.
• the compound according to this embodiment is such that: • Ri, R 2 are each an ethyl radical; • R 3 is a C 5 -C 17 unsubstituted linear alkyl or alkenyl radical; and • n is equal to 1.
• the compound used according to the invention is such that: • Ri, R 2 are each an ethyl radical; • R 3 is a linear C 8 -C 2 o unsubstituted alkyl or alkenyl radical; and • n is statistically between 4 and 5.
• the compound of formula (I) is such that: • Ri, R 2 form, with the nitrogen atom to which they are linked, a piperidine or pyrrolidine ring substituted by a phenyl, benzyl, 2-phenyl-ethyl or 3-phenyl propyl; • R 3 is a linear C 5 -C 17 unsubstituted alkyl radical, preferably an undecyl radical; and • n is equal to i.
• the compounds according to this embodiment can be prepared according to a two-step process, comprising:
• step (b) the reaction of the product obtained in step (a) with the acyl chloride Rs-CO-CI, in the presence of triethylamine in dichloromethane, at room temperature, as indicated above (route A).
• the Applicant has demonstrated a dermo-relaxing and muscle relaxant effect of the compounds according to the invention, which makes it possible to envisage their use, more particularly in the smoothing of expression lines.
• the invention therefore also relates to the cosmetic use of at least one compound as defined above, in a composition suitable for topical application to the skin, as an agent intended to smooth wrinkles, in particular of expression. .
• the Applicant has moreover demonstrated that some of the compounds used according to the invention were new and exhibited an interesting dermo-relaxing or muscle relaxant activity.
• the invention therefore also relates to a subfamily of compounds derived from ((dialkylamino) alkoxy) ethanol, chosen from the esters which correspond to formula (II) below:
• esters of formula (II) are such that R is chosen from the radicals n- ,,,,,...: yl, n-nonyl, n-undecyl, n- tridecyl, n-pentadecyl, n-heptadecyl; ecadienyl (corresponding to linoleate).
• R is chosen from the radicals n- ,,,,,...: yl, n-nonyl, n-undecyl, n- tridecyl, n-pentadecyl, n-heptadecyl; ecadienyl (corresponding to linoleate).
• a preferred compound is such
• (III) 4 denotes a linear, branched or cyclic C 2 -C 21 alkyl or alkenyl group or an aryl group which may be substituted by at least one radical chosen from: a cycloalkyl radical; phenyl optionally substituted by one or more radicals chosen from the radicals OR ', COOR', linear or branched CC 6 and CF 3 alkyl; GOLD'; -COOR '; and -NR'R "; where R 'and R" independently denote a hydrogen atom or a linear or branched CC 6 alkyl or alkenyl group;
• R 5 denotes a phenyl, benzyl, 2-phenyl-ethyl or 3-phenyl propyl group
• n 1 or 2.
• the acid or base used to salify the esters of formulas (II) and (III) may be any physiologically acceptable acid or base, as defined above.
• the subject of the present invention is also a composition, in particular suitable for topical application to the skin, comprising, in a physiologically acceptable medium, at least one compound chosen from esters corresponding to formula (II) or (III) and their addition salts with an acid or a base.
• esters of formula (I) -and therefore of formulas (II) or (III) - which can be used according to the invention and or their salts is of course dependent on the desired effect and can therefore vary to a large extent .
• these compounds can be used in an amount representing from 0.01% to 10% of the total weight of the composition, preferably in an amount representing from 0.05% to 5% of the total weight of the composition , more preferably in an amount representing from 0.1% to 2% of the total weight of the composition.
• composition according to the invention is suitable for topical application to the skin and therefore it contains a physiologically acceptable medium, that is to say compatible with the skin and optionally with its integuments (eyelashes, nails, hair) and / or mucous.
• This medium is advantageously cosmetically acceptable, that is to say that it does not cause itching, tingling or redness liable to to divert the user from the composition, and that he has a pleasant appearance, odor and touch.
• This composition can be in all dosage forms normally used in the cosmetic field, and it can in particular be in the form of an optionally gelled solution, of a dispersion of the lotion type, optionally two-phase, of an emulsion obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of a triple emulsion (W / O / W or O / W / O) or of a vesicular dispersion of ionic type and / or non-ionic.
• These compositions are prepared according to the usual methods. It is preferred to use according to this invention a composition in the form of an oil-in-water emulsion.
• This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied in the form of an aerosol. It can also be in solid form, in particular in the form of a stick. It can be used as a care product and / or as a make-up product for the skin.
• the composition used according to the invention may also contain the adjuvants usual in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers , filters, pigments, odor absorbers and coloring materials.
• the amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition.
• These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase or into the lipid vesicles. In any event, these adjuvants, as well as their proportions, will be chosen so as not to harm the desired properties of the compounds according to the invention.
• the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
• the oils, emulsifiers and co-emulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
• the emulsifier and the co-emulsifier are present in the composition in a proportion ranging from 0.3 to 30 % by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
• oils which can be used in the invention mention may be made of mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin), synthesis (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers).
• mineral oils mineral jelly oil
• oils of vegetable origin oils of vegetable origin
• lanolin oils of animal origin
• synthesis perhydrosqualene
• silicone oils cyclomethicone
• fluorinated oils perfluoropolyethers
• Fatty alcohols cetyl alcohol
• fatty acids fatty acids
• waxes can also be used as fat.
• emulsifiers and co-emulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-100 stearate, and fatty acid and glycerin esters such as stearate glyceryl.
• hydrophilic gelling agents / thickeners mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as gelling agents / thickeners lipophilic, there may be mentioned modified clays such as bentones, metal salts of fatty acids, and hydrophobic silica.
• retinol and its derivatives such as retinyl palmitate; ascorbic acid and its derivatives such as magnesium ascorbyl phosphate and ascorbyl glucoside; tocopherol and its derivatives such as tocopheryl acetate; nicotinic acid and its precursors such as nicotinamide; ubiquinone; glutathione and its precursors such as L-2-oxothiazolidine-4-carboxylic acid; plant extracts and in particular plant proteins and their hydrolysates, as well as phytohormones; marine extracts such as algae extracts; bacterial extracts; sapogenins such as diosgenin and Wild Yam extracts containing them; ceramides; hydroxy acids; hydroxy acids, such as salicylic acid and n-octanoyl-5-salicylic acid; resveratrol; oligopeptides and pseudodipeptides and their acylated derivatives; manganese and
• composition according to the invention may also contain photo-protective agents active in UVA and / or UVB, in the form of organic or inorganic compounds, the latter being optionally coated to make them hydrophobic.
• the organic photo-protective agents can in particular be chosen from: anthranilates, in particular menthyl anthranilate; benzophenones, in particular benzophenone-1, benzophenone-3, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12, and preferably Benzophenone-3 (Oxybenzone), or Benzophenone-4 (Uvinul MS40 available from BASF); benzylidenes-camphors, in particular 3-benzylidene-camphor, benzylidenecamphosulphonic acid, benzalkoniummethosulfate of camphor, polyacrylamidomethylbenzylidene camphor, terephthalylidene di-camphor sulfonic acid, and preferentially 4-methylbenzide at Merck); benzimidazoles, in particular benzimidazilate (Neo Heliopan AP available from Haarmann and Reimer), or phenylbenzimidazole
• the inorganic photo-protective agents preferably consist of zinc oxide and / or titanium dioxide, preferably of nanometric size, optionally coated with alumina and or stearic acid.
• composition according to the invention is advantageously intended to be applied to the areas of the face and / or the forehead marked by expression lines, and / or on people with expression lines.
• the wrinkles concerned are preferably those arranged radially around the mouth and / or the eyes, in particular the crow's feet wrinkles, and / or located at the forehead, in particular the so-called lion's wrinkle, located at the level of the glabella, in the inter-eyebrow space, and / or arranged horizontally on the forehead.
• This process includes the following steps.
• the commercial ((diethylamino) ethoxy) ethanol is dissolved in dichloromethane. 2.1 equivalents of triethylamine are then added, then slowly 1.05 equivalents of RCOCI acid chloride and the mixture is left to react for 20 h at room temperature.
• the medium is diluted with dichloromethane, then two aqueous washes are carried out.
• the organic phase is dried over sodium sulfate, filtered and then concentrated to dryness.
• the residue obtained is purified by column of silica or by precipitation.
• Example 2 Preparation of the ester of coconut fatty acids and ethoxylated (diethylamino) ethanol (n ⁇ 1-9).
• This mixture of compounds can be prepared by direct heating of a mixture of aminoethanol ethoxylates in the presence of coconut fatty acids, with or without solvent.
• the water formed is distilled directly in the case of reaction without solvent, or distilled in the form of an azeotropic mixture with the solvent such as toluene, or even trapped by a desiccant introduced into the reaction medium such as a molecular sieve or any other dehydrating agent.
• the mixture of compounds obtained has an amine number of 1.89 (meq / g) and the following structure:
• R corresponds to a residue of coconut fatty acids and n is statistically between 4 and 5.
• IC 5 oc a2 + for calcium flow inhibition of three compounds according to the invention.
• the results are given in Table 1 below.
• IC 50 c a2 + represents the inhibitory concentration of 50% of Ca 2+ release
• the studies are carried out using homogenates of the cerebral cortex of rats (isolated membranes having calcium channels of the L type on their surface) according to the method described by Reynolds I.J. et al., 1986, J. Pharmacol. Exp. Ther., 237, p.731.
• D888 which is [ 3 H] (-) desmethoxyverapamil serves as a specific radiolabelled ligand and D600 which is ( ⁇ ) methoxyverapamil hydrochloride serves as a reference molecule.
• the specific binding of a ligand (labeled D888) to receptors is defined as the difference between total binding and non-specific binding determined in the presence of an excess of cold ligand (non-radioactive ). The results are expressed as a percentage of inhibition of the specific binding of the control in the presence of the test compound.
• Example 1 inhibits the specific binding of the control to calcium channels by 31%.
• the mixture of compounds of Example 2 inhibits by 95% the specific binding of the control to the calcium channels. From this test and from the teaching of application EP-1 053 745, it is deduced therefrom that these compounds have a high probability of having a beneficial effect on wrinkles and in particular expression wrinkles.
• Example 2 The mixture of compounds of Example 2 was tested on a nerve-muscle co-culture model which makes it possible to recreate a motor arc by innervating human striated muscle cells with explants of spinal cord and spinal ganglia of embryos of rat.
• Protocol Human muscle cells obtained from striations of striated muscles from a healthy donor, are seeded in wells of 1.8 cm 2 in section (24-well culture dishes). After 10 days of culture, these cells form a monolayer and fuse. At this stage, spinal cord explants of 13-day rat embryos containing the spinal ganglia are placed on the culture.
• Co-cultures are used after 21 days, when the muscle fibers are striated and have mature differentiated neuromuscular junctions.
• a muscle fiber having regular contractions (at least 60 contractions per minute) is then selected from three different culture wells and the number of contractions is counted over 30 seconds.
• the test compound diluted in DMSO, is then incubated for 60 seconds in these wells, at the concentration of 10, 50 and 100 ⁇ M. At the end of the incubation, the number of contractions is again counted over 30 seconds. The test is carried out in triplicate.
• the mixture of compounds of Example 2 blocks the contractions of the three referenced muscle fibers, at concentrations of 10, 50 and 100 ⁇ M.
• composition is prepared in a conventional manner for a person skilled in the art. The quantities indicated are in percentages by weight. (Diethylamino) ethoxy) ethanol decanoate 1% Propylene glycol isostearate 13% Polyethylene glycol (8 EO) 5% Propylene glycol 3% Pentylene glycol 3%
• This fluid is intended to be used in single- or twice-daily applications on the face and forehead to reduce expression wrinkles.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Emergency Medicine (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Hematology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Obesity (AREA)
• Diabetes (AREA)
• Rheumatology (AREA)
• Endocrinology (AREA)
• Toxicology (AREA)
• Pain & Pain Management (AREA)
• Neurology (AREA)
• Biochemistry (AREA)
• Physical Education & Sports Medicine (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Hydrogenated Pyridines (AREA)
• Pyrrole Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=34944694

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Family Cites Families (6)

• 2004
  • 2004-05-06 FR FR0404914A patent/FR2869902B1/fr not_active Expired - Fee Related
• 2005
  • 2005-04-18 EP EP05757130A patent/EP1745008A1/de not_active Withdrawn
  • 2005-04-18 US US11/579,593 patent/US20080287537A1/en not_active Abandoned
  • 2005-04-18 JP JP2007512246A patent/JP2007536352A/ja not_active Withdrawn
  • 2005-04-18 WO PCT/FR2005/000927 patent/WO2005121067A1/fr active Application Filing

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events